Status:
UNKNOWN
National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
AstraZeneca
Conditions:
Asthma Chronic
Severe Asthma
Eligibility:
All Genders
18+ years
Brief Summary
The SECOND SOUFFLE survey focuses on aspects of care and quality of life in a period when the landscape of severe asthma is changing in the context of biotherapies. Moreover survey on care pathway and...
Detailed Description
The Th2 phenotype corresponds to severe asthmatic patients eligible for new subcutaneous targeted asthma therapies, which can bring about a real improvement in symptoms and quality of life. No data ar...
Eligibility Criteria
Inclusion
- diagnosis of severe asthma for at least 12 months confirmed by a respiratory physicians and meeting the ATS / ERS definition,
- Social insured patient,
- Patient given the non-opposition
Exclusion
- Patient participating in a therapeutic clinical trial
- Patient opposing participation in this study
- Patient with reading and comprehension difficulties not allowing him to complete the questionnaires
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04438408
Start Date
September 1 2020
End Date
December 1 2021
Last Update
November 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UHToulouse
Toulouse, France, 31000